PriceTargets.com logo

Haleon - HLN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: GBX 356
  • Forecasted Upside: 8.21%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
GBX 329 As of 05/17/2024 01:00 AM ET
▼ -3.4 (-1.02%)

This chart shows the closing price for HLN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Haleon Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HLN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HLN

Analyst Price Target is GBX 356
▲ +8.21% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Haleon in the last 3 months. The average price target is GBX 356, with a high forecast of GBX 387 and a low forecast of GBX 280. The average price target represents a 8.21% upside from the last price of GBX 329.

This chart shows the closing price for HLN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 polled investment analysts is to hold stock in Haleon. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/24/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/22/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/21/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/19/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/17/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/17/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/18/2024HSBCInitiated CoverageBuy
4/9/2024BarclaysLower TargetOverweightGBX 390 ➝ GBX 383
11/6/2023BarclaysBoost TargetOverweightGBX 367 ➝ GBX 391
10/11/2023Deutsche Bank AktiengesellschaftBoost TargetGBX 340 ➝ GBX 360
10/10/2023BarclaysLower TargetGBX 381 ➝ GBX 367
10/10/2023JPMorgan Chase & Co.Reiterated RatingUnderweightGBX 280
8/9/2023Credit Suisse GroupLower TargetGBX 390 ➝ GBX 387
8/9/2023Morgan StanleyLower TargetGBX 375 ➝ GBX 370
7/4/2023Deutsche Bank AktiengesellschaftLower TargetGBX 350 ➝ GBX 340
7/4/2023BarclaysLower TargetGBX 400 ➝ GBX 378
5/4/2023BarclaysBoost TargetGBX 383 ➝ GBX 400
5/4/2023JPMorgan Chase & Co.Boost TargetGBX 250 ➝ GBX 280
4/20/2023Credit Suisse GroupBoost TargetGBX 372 ➝ GBX 390
4/19/2023Deutsche Bank AktiengesellschaftBoost TargetGBX 300 ➝ GBX 350
4/18/2023Morgan StanleyBoost TargetGBX 360 ➝ GBX 375
4/12/2023BarclaysBoost TargetOverweightGBX 364 ➝ GBX 383
3/7/2023Morgan StanleyLower TargetGBX 370 ➝ GBX 360
3/7/2023Bank of AmericaLower TargetGBX 358 ➝ GBX 344
3/6/2023Jefferies Financial GroupLower TargetHoldGBX 335 ➝ GBX 330
2/1/2023JPMorgan Chase & Co.Reiterated RatingUnderweightGBX 250
1/31/2023BarclaysBoost TargetOverweightGBX 360 ➝ GBX 364
1/25/2023Credit Suisse GroupReiterated RatingOutperformGBX 376
12/8/2022Deutsche Bank AktiengesellschaftReiterated RatingHoldGBX 300
12/7/2022BarclaysDowngradeOverweightGBX 289 ➝ GBX 360
11/14/2022BarclaysBoost TargetOverweightGBX 850 ➝ GBX 890
11/14/2022Deutsche Bank AktiengesellschaftReiterated RatingHoldGBX 300
11/11/2022BarclaysReiterated RatingEqual WeightGBX 298
11/3/2022Credit Suisse GroupLower TargetGBX 368 ➝ GBX 353
10/28/2022Kepler Capital MarketsInitiated CoverageHold$275.00
10/28/2022CheuvreuxInitiated CoverageHoldGBX 275
9/21/2022Royal Bank of CanadaBoost TargetGBX 300 ➝ GBX 320
9/21/2022JPMorgan Chase & Co.Reiterated RatingUnderweightGBX 250
9/21/2022Deutsche Bank AktiengesellschaftReiterated RatingHoldGBX 300
9/9/2022Deutsche Bank AktiengesellschaftReiterated RatingHoldGBX 300
9/7/2022JPMorgan Chase & Co.Lower TargetUnderweightGBX 280 ➝ GBX 250
8/16/2022Royal Bank of CanadaReiterated RatingSector PerformGBX 300
8/11/2022JPMorgan Chase & Co.Reiterated RatingUnderweightGBX 280
7/21/2022CitigroupReiterated RatingBuyGBX 360
7/19/2022BarclaysUpgradeEqual WeightGBX 348
7/19/2022Credit Suisse GroupReiterated RatingOutperformGBX 368
(Data available from 5/18/2019 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/20/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/19/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/18/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/17/2024
  • 1 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/17/2024

Current Sentiment

  • 1 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Haleon logo
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Read More

Today's Range

Now: GBX 329
Low: 326.80
High: 332.10

50 Day Range

MA: GBX 327.22
Low: 315
High: 339.50

52 Week Range

Now: GBX 329
Low: 306.80
High: 344.15

Volume

39,617,998 shs

Average Volume

18,911,703 shs

Market Capitalization

£30.04 billion

P/E Ratio

2,741.67

Dividend Yield

1.82%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Haleon?

The following Wall Street analysts have issued reports on Haleon in the last year: Barclays PLC, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, HSBC Holdings plc, JPMorgan Chase & Co., and Morgan Stanley.
View the latest analyst ratings for HLN.

What is the current price target for Haleon?

5 Wall Street analysts have set twelve-month price targets for Haleon in the last year. Their average twelve-month price target is GBX 356, suggesting a possible upside of 8.2%. Credit Suisse Group AG has the highest price target set, predicting HLN will reach GBX 387 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of GBX 280 for Haleon in the next year.
View the latest price targets for HLN.

What is the current consensus analyst rating for Haleon?

Haleon currently has 1 sell rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in HLN, but not buy more shares or sell existing shares.
View the latest ratings for HLN.

What other companies compete with Haleon?

Other companies that are similar to Haleon include Smith & Nephew, GSK, Hikma Pharmaceuticals, HUTCHMED and Indivior. Learn More about companies similar to Haleon.

How do I contact Haleon's investor relations team?

Haleon's physical mailing address is The Heights Building 5, First Floor The Heights, Weybridge KT13 0NY, United Kingdom. The company's listed phone number is 44 1932 822000. The official website for Haleon is www.haleon.com. Learn More about contacing Haleon investor relations.